肺动脉高压的干细胞治疗研究进展

The current application of stem cell based therapy in pulmonary hypertension

肺动脉高压是一种病程进展较快、死亡率高的心肺血管疾病,患病率呈逐年上升趋势,正日益受到人们的重视。目前,肺动脉高压的治疗主要针对血管扩张靶向治疗,而如何通过干细胞治疗改善血管重构至今尚未建立有效方案。10余年来,内皮祖细胞、间充质干细胞以及多能干细胞技术取得的长足进步为肺动脉高压患者带来了希望。本文介绍了国内外干细胞技术治疗肺动脉高压的最新研究进展,并针对相关研究中存在的问题进行了讨论。

Pulmonary hypertension（PH） is a progressive cardiopulmonary disease with high mortality and increased prevalence.The target therapy of pulmonary hypertension is mainly dependent on vasodilation,but how to improve vascular remodeling with stem cell therapy has not been fully understood.Over the past ten years,the researches on endothelial progenitor cells,mesenchymal stem cells and pluripotent cells have brought the hope to patients with pulmonary hypertension.This article mainly introduces the latest progress of stem cell technology in the intervention of pulmonary hypertension,and discusses the problems in the application.